© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Ceftazidime took shape during a period when scientists searched for fresh answers to stubborn bacterial infections. Doctors started running into bugs that shrugged off earlier antibiotics. Researchers reached into the cephalosporin class for inspiration, tweaking molecules to challenge resistance. Ceftazidime arrived in the market in the 1980s, an answer to hospital-acquired infections, and hospitals quickly made use of its broad spectrum, especially against Pseudomonas aeruginosa. Pharmaceutical teams then developed Ceftazidime in its sodium carbonate salt form, improving its stability and preparation for injection. Adding sodium carbonate solved solubility and shelf life concerns, which meant hospitals could store and administer the antibiotic with more confidence. This approach met everyday needs on the hospital floor, not just abstract ideals in a lab.
Ceftazidime sodium carbonate is an injectable form of a third-generation cephalosporin antibiotic. In practice, you see it supplied as a dry powder in sterile vials. Medical staff mix it with water before giving it to patients. It binds to bacterial penicillin-binding proteins, disrupting cell wall synthesis, and bacteria can't survive this assault. This product stands out for battling tough infections stemming from Gram-negative organisms, even when other options have fallen short. For doctors and pharmacists, this means one more tool when other antibiotics fail, not just another generic medication.
This compound appears as a white to pale yellow crystalline powder. It dissolves in water, producing a solution suited for intravenous or intramuscular injection. The sodium carbonate component helps buffer the solution, controlling its pH. Maintaining consistent pH helps keep the ceftazidime molecule from breaking down during storage or after reconstitution. Its chemical stability remains a key strength—medical staff rely on this property since deteriorating antibiotics risk lowered potency or increased side effects. Molecular weight clocks in around 546 g/mol, and its chemical formula reads C22H22N6O7S2·Na2CO3. A precise melting point helps with quality control and tells chemists if their batch matches specifications. Moisture sensitivity means manufacturers use airtight containers, and pharmacists don’t leave vials open to air.
Clear labeling keeps patients safe and helps hospital staff avoid costly mistakes. Ceftazidime sodium carbonate vials show strength per vial (typically 1g or 2g), expiration dates, storage instructions, batch numbers, and instructions for proper reconstitution. Manufacturers run each batch through quality checks for purity, sterility, and potency before products reach pharmacies. Compendial standards from the United States Pharmacopeia (USP) or the European Pharmacopeia guide these efforts. Reliable packaging includes tamper-evident seals and color-coding, useful tricks to prevent confusion among similar-looking antibiotics. These standards might sound routine, but missing details cause real harm in a busy hospital pharmacy.
Engineers set up multistep processes to get ceftazidime sodium carbonate ready for hospitals. Synthesis steps produce raw ceftazidime, followed by a reaction with sodium carbonate. Chemists dry the final material using vacuum drying or lyophilization. Each step removes impurities. Automated machines measure and fill vials in cleanrooms, keeping out microbes, dust, and even stray human skin cells. Vials are then stoppered and sealed while still clean. Most modern facilities run everything on a schedule, with sample testing at every stage. The most respected facilities track everything from the source of chemicals used to the results of the sterility test, keeping paperwork in order for each shipment.
Ceftazidime’s core structure comes from a 7-aminocephalosporanic acid backbone. Chemical modifications at various positions—such as the side chain at position 3—can change how the antibiotic gets absorbed or how it interacts with bacterial enzymes. These modifications allow ceftazidime sodium carbonate to shrug off certain β-lactamases, enzymes that bacteria use to neutralize penicillins and first-generation cephalosporins. Once sodium carbonate salts form, they help buffer the drug during preparation and injection, avoiding sudden drops or spikes in acidity that can irritate tissue or inactivate the medicine. Researchers still dig into further tweaks, targeting more persistent forms of resistance or special clinical needs.
You might see ceftazidime sodium carbonate listed under a few different names: Fortaz, Tazicef, or Ceptaz, depending on the manufacturer and region. International medical catalogues sometimes list its formal name as ceftazidime disodium carbonate, ceftazidime sodium salt buffered, or simply ceftazidime for injection. Nurses and pharmacists get used to these names quickly—mistaking one for another seems rare, but good training and barcoding limit risk even more.
Hospitals hold strict rules for storing and using ceftazidime sodium carbonate. Vials get stored at temperatures under 25°C, away from light and humidity. Pharmacy technicians and nurses wear gloves when handling vials and discard mixed solutions after 12 hours at room temperature or 24 hours in the fridge. Exposure to air or heat breaks the chemical structure or draws in moisture, leading to lost potency. Double-checking labels stops dosing errors. Regulatory agencies, including the FDA and EMA, lay out clear operational standards. Staff follow protocols for cleaning spills, disposing of unused product, and tracking any adverse reactions. Safety data sheets include information on inhalation, skin contact, and environmental concerns. While basic in concept, these habits keep hospital wards running without unnecessary infection or accidental injury.
Doctors use ceftazidime sodium carbonate for tough cases: pneumonia acquired at the hospital, serious urinary tract infections, septicemia, and infections from burns or wounds. Hospitals depend on it for ventilator-associated pneumonia, where Pseudomonas aeruginosa and other Gram-negative bacilli thrive. Surgeons turn to it during outbreaks of resistant bacteria in intensive care settings. Beyond its human use, researchers study the drug in animal models to predict benefit against emerging resistant strains. Its role stretches beyond hospital floors into veterinary medicine and, sometimes, into environmental testing for antibiotic resistance spread.
Scientists keep searching for improved formulations and combinations. Current projects include coupling ceftazidime with new β-lactamase inhibitors or making long-acting depot injections for outpatient use. Modern analytical labs now scan for impurities at the nanogram level, picking up changes that signal process drift or substandard batches. Academic teams mine bacterial genomes, learning how mutations change susceptibility to ceftazidime and suggesting approaches to revive its usefulness. In addition, digital tracking tools help epidemiologists trace outbreaks where resistant infections seem to follow ceftazidime exposure. Researchers team up with industry and public health labs, aiming to translate every new insight into practical benefit.
Ceftazidime sodium carbonate shows a reassuring safety profile when used correctly, but research flags important side effects. In rare cases, patients may experience allergic reactions, ranging from rash to dangerous anaphylaxis. Dose adjustments become essential in people with kidney impairment, since the drug clears in urine and can build up otherwise, leading to seizures or confusion. Researchers watch for patterns of toxicity—some caused by the main drug, others linked to the sodium load in sensitive patients. Animal studies and post-market surveillance feed into updated warnings and dosing guidance. These lessons enter practice quickly, as real-world cases can move fast and escalate without warning.
Ceftazidime sodium carbonate faces fresh challenges and opportunities. Bacterial resistance keeps pushing, but ongoing development to new β-lactamase inhibitors promises renewed strength. Some companies look toward delivery through extended-release formulations, making dosing easier for home care settings. Hospitals keep pushing for “antibiotic stewardship,” meaning smart, targeted use, so future research looks at real-world effectiveness and new diagnostics to guide therapy. Efforts to lower costs, improve access, and adjust packaging for low-resourced areas also gain traction. At industry conferences, discussion moves beyond saying “another antibiotic”—instead, there’s a push to treat the right patient, at the right time, with as few side effects and hospital days as possible.
Anyone who has worked long shifts in a hospital ward knows the pressure that comes when a patient develops a stubborn infection. Some days, the standard antibiotics start to lose ground. That’s where medicines like ceftazidime sodium carbonate step into the spotlight. This compound isn’t just another item on a pharmacist’s shelf—it’s a critical part of the toolkit for handling tough bacterial infections, especially those attacking patients with weaker immune systems.
Ceftazidime belongs to the third generation of cephalosporin antibiotics, and it packs a punch against a range of Gram-negative bacteria. Hospitals often turn to it for infections such as pneumonia, urinary tract infections, sepsis, and even infections that set up shop in wounds or surgical sites. I remember a case where a patient, recovering from surgery, started showing rising fevers. Tests pointed to Pseudomonas—a notorious, resistant bug often found lurking on hospital surfaces. Common antibiotics could not contain it, but with ceftazidime, we saw a turnaround.
This medicine shows particular strength against Pseudomonas aeruginosa, a bacteria most doctors learn to fear. Regular antibiotics often fail because these bacteria adapt fast. Ceftazidime’s unique structure lets it target a wider range of bacteria than older cephalosporins could manage. It’s not a cure-all, but at times, it feels like a lifeline for patients whose options have narrowed.
People ask about the sodium carbonate part. It matters more than it might seem. Sodium carbonate stabilizes the ceftazidime in solution, making it safe to deliver by intravenous injection. Without this addition, the medicine breaks down too fast, and its bacteria-fighting power drops before even reaching the bloodstream. Anyone who has mixed up antibiotics for IV use can appreciate the care that goes into keeping the medicine active long enough to help the patient.
A strong medicine like ceftazidime shouldn’t be handed out lightly. Overusing it risks breeding bacteria that can stand up to even more powerful antibiotics, and that poses a threat for every patient who comes through the door. Resistant Pseudomonas and other Gram-negative bacteria haunt intensive care units from New York to Mumbai. For that reason, infectious diseases teams work alongside pharmacists to track how—and when—these antibiotics get prescribed.
Education in hospitals can’t stop after medical school. Every year brings new bacteria with new tricks for dodging treatment. Fact: according to the CDC, nearly three million Americans face antibiotic-resistant infections each year, and more than 35,000 do not survive. That makes stewardship—meaning careful control of antibiotic use—essential. Hospitals set up guidelines, monitor prescriptions, and push for diagnostic tests before reaching for drugs like ceftazidime. This slows resistance and keeps options open for those critically ill.
No single medicine solves every problem. Ceftazidime sodium carbonate stands out for its reliability, but its value remains only with thoughtful use. Health professionals, patients, and even families need to stay mindful about antibiotics. The future of infection care depends on balancing short-term wins against long-term risks. My own experience bears out how much of a difference these conversations make. By pulling together as a team—patient, nurse, doctor, pharmacist—we give each dose of ceftazidime the chance to really count.
Ceftazidime Sodium Carbonate steps up as a crucial antibiotic, especially for people dealing with tough infections. Many hospitals count on it in the fight against bacteria that ignore other drugs. I remember more than one night in the hospital watching nurses prepare ceftazidime for patients who had already tried several other antibiotics without success. Its role matters most when the stakes are high and ordinary antibiotics just won’t do the trick. This drug treats everything from severe lung and urinary tract infections to meningitis and infections in people with weakened immune systems.
Doctors don’t reach for ceftazidime unless they know a few important things about the patient. They check kidney function, look into allergies, and always ask if the patient had any trouble with penicillin before. Ceftazidime belongs to the cephalosporin family, so anyone with a history of severe reactions may face real risks. In my clinical rounds, I witnessed pharmacists double-checking prescriptions and chatting with doctors about alternative drugs for someone with kidney trouble, since ceftazidime stays longer in the body if kidneys aren’t filtering well.
Nurses or pharmacists usually do all the work of mixing the powder with sterile water. Each vial contains a measured dose, so accuracy stays high. The powder dissolves into a clear liquid that goes directly into a vein, using either a slow injection or a drip over 30 minutes. Hospital guidelines stress the importance of giving the drug pretty soon after mixing it; letting it sit too long reduces its strength. One night, a nurse showed me how the freshly mixed drug must go up right away for patients with sepsis. These details matter. If the medicine sits for hours on the shelf, patients don’t get the full benefit.
Doctors usually order ceftazidime for adults at doses between 1 and 2 grams, usually every 8 or 12 hours. The decision on how much and how often rests on the type and severity of infection, plus the patient’s kidney function. For those with poor kidneys, the usual plan requires lower doses or longer gaps between doses. This careful adjustment goes far toward protecting patients from side effects like seizures or kidney irritation. Hospitals rely on lab tests to guide these decisions, but talking with patients about how they feel provides equally crucial information.
Sometimes, skipping a dose or giving too much by accident causes problems. Staff run through checklists before every administration. They match patient names, double check allergies, and scan barcodes on both medicine and wristbands. This attention to detail pays off. In one pediatric ward, a barcode scanner alert caught a potential error before the drug reached the patient’s IV.
One of the big challenges, especially in smaller clinics, involves access to quick lab testing and staff training. Hospitals with digital record systems and drug-tracking technology help cut down mistakes. A steady hand and a habit of asking questions support safe practices. For home-care cases, pharmacists must provide clear instructions and sometimes offer in-person mixing demonstrations. Family members and patients need space to ask every awkward question, so they know how to store, mix, and administer the medication safely and without panic.
More hospitals invest in e-learning tools for nurses and caregivers, bringing fresh knowledge on antibiotics like ceftazidime to those working night shifts or in understaffed areas. Building a culture of teamwork turns out to be the most effective way to safeguard patients and make sure ceftazidime does its job in the fight against serious infections.
Doctors rely on ceftazidime sodium carbonate when people face tough bacterial infections. Hospitals often go with this antibiotic for pneumonia, urinary tract infections, or infections in the abdomen. Its broad reach makes it a regular option in serious settings where quick, reliable results matter. As a parent who watched my child get a ceftazidime injection after appendicitis, I saw firsthand both relief at recovery and worry over how the body reacts to strong medicine.
Gastrointestinal side effects stand out for many patients. After a few doses, some folks feel mild nausea, sometimes accompanied by vomiting or loose stools. Stomach upset can sneak up without warning. My neighbor, who takes this antibiotic for recurring UTIs, finds she needs bland foods to settle her stomach during the course.
Experience with ceftazidime sometimes involves diarrhea. Most research from clinical studies puts this number at about 5-10% of users. Patients might pass off mild symptoms as normal until cramps or more frequent bathroom trips remind them to mention it to their doctor. These symptoms usually fade after finishing the medication, but persistent, severe diarrhea deserves medical attention right away—especially since antibiotic use can trigger more serious gut conditions like Clostridioides difficile infection.
My time volunteering at a community clinic showed how seriously doctors take penicillin or cephalosporin allergies. Small numbers of people, according to Centers for Disease Control data, may develop rashes, itching, or swelling. Shortness of breath and low blood pressure can point to a dangerous allergic response. Anyone who breaks out in hives or has trouble breathing needs emergency care.
People with documented allergies to similar antibiotics should share this information upfront with their care team. Allergic reactions rarely show up out of the blue, but some individuals without any history might still have a surprise reaction. Keeping emergency contacts and allergy information handy on a medical ID or phone can save precious minutes in these situations.
Headaches and dizziness sometimes pop up. In most cases, these aren’t deal-breakers but bring extra discomfort. Some patients mention feeling tired or off-balance during their course. These experiences remind us that even necessary medicine can interrupt routines and remind people of their vulnerability.
On the bloodwork side, doctors may notice changes in liver or kidney function tests, or counts for white or red blood cells. These values help guide treatment, especially during long courses or in people with pre-existing conditions. Checking labs before and during treatment keeps surprises low. Monitoring makes it easier to spot trends before they cause serious trouble.
Caring for folks on ceftazidime starts with honest conversation. Hospital staff should encourage people to mention every symptom, even if it feels small. Changing timing of doses, adjusting diet, or prescribing probiotics can ease some symptoms like digestive upset. For repeated courses, checking for superinfections or secondary fungal infections keeps people out of harm’s way.
Staying informed, recognizing changes in your own body, and keeping in close touch with a trusted health care provider set the stage for a safer and more comfortable recovery. With advanced monitoring and careful case selection, patients get the benefits of ceftazidime while sidestepping preventable problems.
Antibiotics have saved countless lives, but not every option works for everyone, and Ceftazidime Sodium Carbonate speaks volumes about the need to check the details carefully before starting a course. This drug does a great job at targeting stubborn gram-negative bacteria, especially Pseudomonas aeruginosa. Infections in hospitals often call for something this strong. Still, strong medicine sometimes brings tricky trade-offs.
If someone has ever had an allergic reaction to other cephalosporins (like cefalexin or ceftriaxone), using ceftazidime brings a risk they shouldn't ignore. Even people with penicillin allergies need to think twice, since cross-reactions show up in a small but real percentage. A study in Clinical Infectious Diseases pinpoints the risk between 1% and 10%. Hives, breathing trouble, or swelling that resulted from antibiotics in the past mean this choice requires a hard pause and a talk with the prescriber.
The kidneys pull a lot of weight clearing this drug from the body. Someone dealing with chronic kidney disease or on dialysis can end up with high levels of ceftazidime in the bloodstream, which raises the risk for side effects like seizures and confusion. Dose adjustments make a huge difference. Doctors often turn to bloodwork before prescribing and adjust as needed, following evidence-based guidelines from groups like the Infectious Diseases Society of America.
Gut side effects take more than a back seat. Ceftazidime can tip the balance in the intestines, making way for infections like Clostridioides difficile. This bacteria explodes in the gut once healthy flora get wiped out, leading to severe diarrhea and sometimes even life-threatening colitis. Over the years, clinicians have learned not to prescribe antibiotics for just any fever or sniffle. Thoughtful prescribing, watching for diarrhea, and quick action help catch these cases before they spiral out of control.
There's not a ton of research on the safety of ceftazidime during human pregnancy. Most evidence comes from animal studies, which don’t always match up with the effects in people. Doctors weigh the risks and benefits heavily, leaning toward safer alternatives when possible, but sometimes the infection itself leaves no other choice. For breastfeeding mothers, small amounts pass into breast milk. Doctors and parents keep an eye out for loose stools or rashes in babies who might get exposed.
Combining ceftazidime with other drugs can spell trouble. Diuretics like furosemide and potent antibiotics such as aminoglycosides can stress the kidneys even more. Regular review of meds – a straightforward medication reconciliation – cuts down the risk. Pharmacists often double-check here, serving as a second set of eyes.
Clear conversations between patient and prescriber stand out as the strongest protection. Listing every medication and allergy before treatment starts goes a long way. Routine labs during therapy, careful dose adjustments, and watching for symptoms of side effects make a real impact. Sticking only to essential antibiotics, and for just long enough, means fewer problems later down the line.
Ceftazidime Sodium Carbonate plays a vital role in treating severe infections caused by bacteria, including hospital-acquired pneumonia, complicated urinary tract infections, and septicemia. The numbers matter, and people’s lives hinge on getting the right dosage. The rules for how much medicine to give don’t leave much room for guesswork. Medical experts and health organizations have set specific guidelines based on research, real-life cases, and review of side effects.
Adults with standard kidney function typically get between 1 to 2 grams of ceftazidime every 8 to 12 hours, injected either intravenously or intramuscularly, depending on the gravity of the infection. For tough cases such as bacterial meningitis, dosages rise to 2 grams every 8 hours. Doctors factor in details like infection site, how serious the infection is, and the presence of other health problems. Dosing isn’t set in stone—patients with kidney problems need a lower dose to keep their safety net intact.
Over years of reporting from hospital floors to rural clinics, I’ve seen what can happen when doctors don’t pay close attention to renal function. Patients get side effects such as seizures, confusion, and even kidney injury. Evidence shows that healthcare providers must check creatinine clearance (a measure of kidney function) before they decide on the right amount. Sometimes that means halving the usual dose for a frail older person or someone on dialysis. Journals like the Journal of Antimicrobial Chemotherapy put these guidelines up for everyone to review, and the consensus supports adjusting for kidney function, no matter the pressure to treat quickly.
Children are not small adults. For those aged over 2 months, the generally accepted dose sits at 30 to 50 mg per kilogram of body weight, every 8 hours. Serious infections such as meningitis push this up to 50 mg/kg, sometimes every 6 hours, but not surpassing 6 grams in one day. Newborns and babies under 2 months have adjustments—lower dosages and longer times between doses due to their immature kidneys.
In my experience, pediatricians lean on multi-disciplinary teams to double and triple-check every calculation. Kids deal with medicine differently. Underdosing might allow infection to linger or worsen; too high a dose might cause brain or kidney injury. National guidelines like those from the British National Formulary for Children help set the rules, but doctors keep an eye on each child, tweaking the numbers if the patient loses weight, takes other antibiotics, or struggles with kidney or liver problems.
Giving the right dose isn’t just about math. Medication error reports show how slips in calculation or record-keeping can harm patients. Electronic medical records and smart pumps help prevent mistakes, but every hospital needs continuing education. Pharmacists catch a good share of errors because they review dosing guidelines daily. Families who ask “What’s a safe dose for my loved one?” deserve real answers, not handwaving.
Antibiotic resistance remains a constant threat. The World Health Organization warns that underdosing or too much antibiotic gives bacteria a chance to evolve. The lesson: hit the right dose, follow expert guidelines, and watch kidney function closely. For tough choices, infectious disease specialists have the most up-to-date training.
| Names | |
| Preferred IUPAC name | Sodium (6R,7R)-7-{2-(2-amino-1,3-thiazol-4-yl)-2-[(Z)-2-carboxypropen-1-yloxyimino]acetamido}-3-(pyridinium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate carbonate |
| Other names |
Ceftazidime Sodium Bicarbonate Ceftazidime and Sodium Carbonate Combination Ceftazidime Disodium Carbonate |
| Pronunciation | /ˌsɛf.təˈzɪ.diːm ˈsəʊ.di.əm ˈkɑː.bə.neɪt/ |
| Identifiers | |
| CAS Number | 94984-11-1 |
| Beilstein Reference | 60587 |
| ChEBI | CHEBI:3573 |
| ChEMBL | CHEMBL34259 |
| ChemSpider | 285105 |
| DrugBank | DB00438 |
| ECHA InfoCard | 03f15963-d473-4934-9770-bc146673ea30 |
| EC Number | 64987-97-9 |
| Gmelin Reference | 1186925 |
| KEGG | **D03524** |
| MeSH | D000069244 |
| PubChem CID | 16219732 |
| RTECS number | VP8040000 |
| UNII | 82YR4562J5 |
| UN number | 3466 |
| CompTox Dashboard (EPA) | DTXSID10982274 |
| Properties | |
| Chemical formula | C15H16N5NaO7S2 |
| Molar mass | 546.48 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | Density: 1.93 g/cm³ |
| Solubility in water | Freely soluble in water |
| log P | -2.64 |
| Acidity (pKa) | 2.8 |
| Basicity (pKb) | 10.66 |
| Magnetic susceptibility (χ) | -44.1×10⁻⁶ cm³/mol |
| Dipole moment | 5.7 D |
| Pharmacology | |
| ATC code | J01DD02 |
| Hazards | |
| Main hazards | May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| GHS labelling | GHS05, GHS07 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | Hazard statements: Causes serious eye irritation. May cause respiratory irritation. |
| Precautionary statements | P264, P270, P301+P312, P330, P501 |
| Lethal dose or concentration | LD₅₀ (mouse, IV): 5200 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse intravenous LD50 = 0.631 g/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL (Permissible exposure limit) for Ceftazidime Sodium Carbonate: Not established |
| REL (Recommended) | 1 to 2 g every 8 to 12 hours |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Cefotaxime Ceftriaxone Cefepime Cefoperazone Ceftazidime Cefuroxime Cefixime Cefazolin |
